Epizyme took in a $4 million in milestone payments from partner GlaxoSmithKline ($GSK) after achieving some pre-clinical goals in the epigenetic alliance announced in January 2010. With up to $630 million in total milestones at stake for Epizyme in the deal, the Cambridge, MA-based developer (a 2011 Fierce 15 company) is working with GSK on small molecules that home in on epigenetic enzymes called histone methyltransferases to combat cancer and other illnesses. Release